Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -- | 6.03M | -1.48M | -3.48M | -5.71M |
| Total Depreciation and Amortization | -- | 27.10K | 27.60K | 26.50K | 24.70K |
| Total Amortization of Deferred Charges | -- | 105.20K | 92.20K | 80.70K | 70.70K |
| Total Other Non-Cash Items | -- | 161.70K | -1.15M | 241.00K | 104.90K |
| Change in Net Operating Assets | -- | -1.64M | 779.50K | 701.30K | 3.65M |
| Cash from Operations | -- | 4.69M | -1.72M | -2.43M | -1.86M |
| Capital Expenditure | -- | 0.00 | -15.10K | 0.00 | -14.40K |
| Sale of Property, Plant, and Equipment | -- | 300.00 | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -65.30K | -24.30K | -72.00K | -64.50K |
| Cash from Investing | -- | -65.00K | -39.40K | -72.00K | -78.90K |
| Total Debt Issued | -- | 300.00K | -- | 0.00 | 1.00M |
| Total Debt Repaid | -- | -504.50K | -200.50K | -64.70K | 0.00 |
| Issuance of Common Stock | -- | 643.80K | -- | 0.00 | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | 1.10M | -- | 0.00 | 6.17M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -54.60K | -- | -35.10K | -963.30K |
| Cash from Financing | -- | 1.48M | -200.50K | -99.80K | 6.21M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 6.11M | -1.96M | -2.60M | 4.27M |
